Danaher Corporation (DHR)
Danaher Corporation (DHR) carries a ŷRobot AI score of 73 out of 100. The model's fair value estimate is $251.99, 8.1% above the last close of $233.02. The chart signal reads Sell.
| Metric | DHR |
|---|---|
| AI score | 73 / 100 |
| Chart signal | Sell |
| Fair value estimate | $251.99 |
| Upside to fair value | 8.1% |
| Previous close | $233.02 |
| P/E | 38.04 |
| Price / sales | 6.33 |
| Market cap | $163.33B |
| EPS | 6.04 |
| Revenue growth | -2.5% |
| 1-year price change | 3.8% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about DHR
Is DHR overvalued or undervalued right now?
As of Oct 24, 2026, ŷRobot's fair-value model estimates Danaher Corporation (DHR) at $251.99 against a last close of $233.02, implying 8.1% upside to the model's estimate.
Is DHR's chart signal bullish or bearish?
The chart-signal model classifies DHR as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is DHR's ŷRobot AI score?
DHR scores 73 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is DHR stock expensive on P/E and P/S?
DHR trades at 38.0 times earnings and 6.3 times sales as of Nov 13, 2026.
What does DHR's seasonal forecast show?
ŷRobot's seasonal forecast curve for DHR reads +2.6% at 30 days, +2.8% at 90 days, and +3.8% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is DHR growing?
Danaher Corporation's revenue growth is -2.5% and free-cash-flow growth is -2.3% on the latest reported figures.
DHR chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.